Screener
Halozyme Therapeutics HALO Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's total equity?
- Halozyme Therapeutics (HALO) reported total equity of $143.54M in Q2 2026.
- How has Halozyme Therapeutics's total equity changed year-over-year?
- Halozyme Therapeutics's total equity decreased by 56.9% year-over-year, from $332.75M to $143.54M.
- What is the long-term trend for Halozyme Therapeutics's total equity?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total equity has grown at a -20.2% compound annual growth rate (CAGR), from $151.05M to $48.81M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Halozyme Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude